NCT04001634已完成不适用
Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in Metastatic HER2-positive Breast Cancer Patients- a Multicenter Retrospective Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 285
- 试验地点
- 1
- 主要终点
- ORR
研究概览
简要总结
To explore the real world situation of trastuzumab and lapatinib combined chemotherapy in China, and to explore the relationship between progression free survival and treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •woman, age > 18 years old
- •Diagnosed with HER2 +Metastatic Breast Cancer
- •Dual anti-HER2 therapy (lapatinib and trastuzumab) plus chemotherapy for at least one cycle, starting from 2013.09.01-2019.07.31
- •Available medical history
排除标准
- •Incomplete medical history
结局指标
主要结局
ORR
时间窗: 6 weeks
Objective Response Rate
PFS
时间窗: 6 weeks
Progression free survival
OS
时间窗: 6 weeks
Overall survival
次要结局
- Treatment Pattern(6 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBCHER2-positive Breast CancerMetastatic Breast CancerNCT04609540Shandong Cancer Hospital and Institute200
尚未招募
不适用
Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI TherapyHER2+ Advanced Breast Cancer Patients Progressing on TKI TherapyNCT05560308Tianjin Medical University Cancer Institute and Hospital50
已完成
2 期
Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract CancerMetastatic Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterSquamous Cell Carcinoma of the BladderStage IV Bladder CancerTransitional Cell Carcinoma of the BladderNCT00005831National Cancer Institute (NCI)40
尚未招募
2 期
Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast CancerHER2-positive Breast CancerNCT04158856xuexin he60
已完成
2 期
Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast CancerNeoplasms, BreastNCT00429299GlaxoSmithKline121